Yasong Lu

Yasong Lu has extensive experience in pharmacometrics and drug development. Yasong is currently serving as the Sr. Director and Head of Pharmacometrics at Bicycle Therapeutics since July 2023. Prior to this, they worked as a Director at Daiichi Sankyo, Inc. from March 2019 to July 2023. Before that, they held the position of Associate Director/Senior Fellow at Novartis, where they played a key role in supporting late-stage development programs in the oncology area by defining pharmacometric strategies, characterizing drug population PK and exposure-response relationships, and authoring analysis reports and regulatory documents. Notably, they secured FDA approval for ribociclib (Kisqali) for advanced breast cancer in 2017. Before their time at Novartis, Yasong Lu served as a Sr. Research Investigator at Bristol-Myers Squibb from September 2012 to January 2016, where they applied pharmacometric analyses to enable drug development in therapeutic areas such as cardiovascular/metabolic diseases and immunosciences. Earlier in their career, they worked at Pfizer as a Sr. Scientist, focusing on applying PK/PD discipline to drug discovery research. Yasong Lu completed their graduate studies at Colorado State University and Shanghai Medical University.

Yasong Lu completed a Bachelor's degree in Preventive Medicine from Shanghai Medical University from 1993 to 1998. After that, they pursued a Master's degree in Environmental Health at the same university, which was completed from 1998 to 2001. Following this, Yasong Lu attended Colorado State University from 2001 to 2006, where they obtained a PhD in Toxicology.